Plus Therapeutics (NASDAQ:PSTV) Trading 2.8% Higher – Still a Buy?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s stock price was up 2.8% on Friday . The company traded as high as $1.45 and last traded at $1.45. Approximately 18,763 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 58,205 shares. The stock had previously closed at $1.41.

Wall Street Analysts Forecast Growth

PSTV has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Plus Therapeutics in a report on Friday, August 16th. Ascendiant Capital Markets lowered their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

Plus Therapeutics Price Performance

The stock’s fifty day moving average is $1.44 and its 200-day moving average is $1.73. The stock has a market capitalization of $8.27 million, a PE ratio of -0.48 and a beta of 0.67.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. The company had revenue of $1.28 million for the quarter. On average, analysts forecast that Plus Therapeutics, Inc. will post -2 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.